Supporting Future Cannabis Policy – Developing a Standard Joint Unit : A Brief Back-Casting Exercise. Hugo López-Pelayo, Silvia Matrai, Mercè Balcells-Olivero, Eugènia Campeny, Fleur Braddick, Matthijs G. Bossong, Olga S. Cruz, Paolo Deluca, Geert Dom, Daniel Feingold, Tom P. Freeman, Pablo Guzman, Chandni Hindocha, Brian C. Kelly, Nienke Liebregts, Valentina Lorenzetti, Jakob Manthey, João Matias, Clara Oliveras, Maria Teresa Pons, Jürgen Rehm, Moritz Rosenkranz, Zoe Swithenbank, Luc van Deurse, Julian Vicente, Mike Vuolo, Marcin Wojnar and Antoni Gual Frontiers in Psychiatry, 2021, 12, 675033. doi : 10.3389/fpsyt.2021.675033 The standardization of cannabis doses is a priority for research, policy-making, clinical and harm-reduction interventions and consumer security. Scientists [...]
Lire la suiteCannabinoids and their therapeutic applications in mental disorders Maria Scherma, PhD; Anna Lisa Muntoni, MD; Gernot Riedel, PhD; Walter Fratta, PhD; Paola Fadda, PhD Dialogues in Clinical Neuroscience, 2020, 22, (3), 271-279. doi : 10.31887/DCNS.2020.22.3/pfadda Mental disorders represent a significant public health burden worldwide due to their high prevalence, chronically disabling nature, and substantial impact on quality of life. Despite growing knowledge of the pathological mechanisms that underlie the development of these disorders, a high percentage of patients do not respond to first-line clinical treatments; thus, there is a strong need for alternative therapeutic approaches. During the past half-century, after the identification of the [...]
Lire la suiteFluorinated Cannabidiol Derivatives: Enhancement of Activity in Mice Models Predictive of Anxiolytic, Antidepressant and Antipsychotic Effects Aviva Breuer, Christeene G. Haj, Manoela V. Fogaça, Felipe V. Gomes, Nicole Rodrigues Silva, João Francisco Pedrazzi, Elaine A. Del Bel, Jaime C. Hallak, José A. Crippa, Antonio W. Zuardi, Raphael Mechoulam, Francisco S. Guimarães PLOS One, 2016, 11, (7), e0158779, 1-19. Doi : 10.1371/journal.pone.0158779 Abstract Cannabidiol (CBD) is a major Cannabis sativa constituent, which does not cause the typical marijuana psychoactivity. However, it has been shown to be active in a numerous pharma- cological assays, including mice tests for anxiety, obsessive-compulsive disorder, depres- sion and schizophrenia. In human [...]
Lire la suiteEditorial: Psychological Aspects of Cannabis Use and Cannabis Use Disorder Daniel Feingold, Eva Hoch, Aviv Weinstein and Wayne Hall Frontiers in Psychiatry, 2021, Volume 12 | Article 789197 doi : 10.3389/fpsyt.2021.789197 Editorial on the Research Topic : Psychological Aspects of Cannabis Use and Cannabis Use Disorder Keywords : cannabis, marijuana, cannabis use disorder, psychology, cognition, emotion An increasing global prevalence of cannabis use has produced increased treatment seeking for Cannabis Use Disorder (CUD) and an increased research effort to identify factors associated with initiation of cannabis use, transitions to regular cannabis use and the onset of CUD (1, 2). The majority of empirical studies focus on biological and [...]
Lire la suiteCannabis and Depression Daniel Feingold, Aviv Weinstein Advances in Experimental medicine and Biology, 2021, 1264, 67-80. In book : "Cannabinoids and Neuropsychiatric Disorders", Aviv Weinstein 's Lab Doi : 10.1007/978-3-030-57369-0_5 Abstract There is a growing body of evidence pointing to the co-occurrence of cannabis use and depression. There is also some evidence that the use of cannabis may lead to the onset of depression; however, strong evidence points to the inverse association; i.e. that depression may lead to the onset or increase in cannabis use frequency. Observational and epidemiological studies have not indicated a positive long-term effect of cannabis use on the course and outcome of [...]
Lire la suiteTHREE NEW STUDIES ON CANNABIS AND PTSD Growing numbers of trauma sufferers are medicating with cannabis and finding it helpful. NATE SELTENRICH 31 décembre 2022 In recent years, psilocybin and MDMA have been explored as potential treatments for post-traumatic stress disorder, but somewhat more quietly so has cannabis. In fact, according to a few quick searches of PubMed, cannabis has a longer and richer association with PTSD in the scientific literature than any psychedelic. Though you wouldn’t know that by reading the headlines. Setting aside for a minute how effective psychedelics may or may not be as breakthrough treatments for PTSD, there’s no doubt that [...]
Lire la suiteAttitudes Toward the Use of Medical Cannabis and the Perceived Efficacy, Side-effects and Risks : A Survey of Patients, Nurses and Physicians Neta HaGani, Sharon Sznitman, Michael Dor, Gil Bar-Sela, Dana Oren, Lilia Margolis-Dorfman, Itay Goor-Aryeh & Manfred S. Green Journal of Psychoactive Drugs, 2021, 1-10. Doi : 10.1080/02791072.2021.2009598 ABSTRACT Gaps between physician and patient perceptions may lead to misunderstandings and mismanage of treatment. There are sparse data about the differences in opinions toward medical cannabis (MC) between patients and health professionals. The aim of this study was to examine the attitudes toward MC, its perceived efficacy, side effects and risk of dependency, among patients, [...]
Lire la suitePosttraumatic stress disorder, sleep and medical cannabis treatment: A daily diary study Sharon R. Sznitman, David Meiri, Ben H. Amit, Dennis Rosenberg, Talya Greene Journal of Anxiety Disorders, 2022, 92, 102632 Doi : 10.1016/j.janxdis.2022.102632 Abstract Despite increasing use of Medical Cannabis (MC) among posttraumatic stress disorder(PTSD) patients, research is lacking on how MC treatment relates to PTSD symptomatology, in particular sleep disturbances. This study examines the time gap between MC use and sleep onset and its association with (1) number of awakenings throughout the night, (2) early awakenings, (3) nightmares. Each morning over a two week period, 77 licensed MC patients suffering from PTSD reported [...]
Lire la suiteAssessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry Manaswini Pillai, Simon Erridge, Lara Bapir, Martha Nicholas, Nishaanth Dalavaye, Carl Holvey, Ross Coomber, Daniela Barros, Urmila Bhoskar, Gracia Mwimba, Kavita Praveen, Chris Symeon, Simmi Sachdeva-Mohan, James J Rucker and Mikael H Sodergren Expert Review of Neurotherapeutics, 2022, 22, 11–12, 1009–1018. Doi : 10.1080/14737175.2022.2155139 ABSTRACT Background : The current paucity of clinical evidence limits the use of cannabis-based medicinal products (CBMPs) in post-traumatic stress disorder (PTSD). This study investigates health-related quality of life (HRQoL) changes and adverse events in patients prescribed CBMPs for PTSD. Methods : A case-series of patients [...]
Lire la suiteIncreased cannabis intake during the COVID-19 pandemic is associated with worsening of depression symptoms in people with PTSD A. Murkar, T. Kendzerska, J. Shlik, L. Quilty, M. Saad and R. Robillard BMC Psychiatry, 2022, 22, 554 Doi : 10.1186/s12888-022-04185-7 Abstract Background: Some evidence suggests substance use affects clinical outcomes in people with posttraumatic stress disorder (PTSD). However, more work is required to examine links between mental health and cannabis use in PTSD during exposure to external stressors such as the COVID-19 pandemic. This study assessed mental health factors in individuals with self-reported PTSD to: (a) determine whether stress, anxiety, and depression symptoms were associ- ated with changes [...]
Lire la suite